New therapy for the prevention and prophylactic treatment of acute radiation syndrome.
The risk of military personnel, first responders and civilians being exposed to lethal doses of ionising radiation is greater now than it was during the Cold War. Due to the increasing likelihood of exposure to ionising radiation, the need for medical radiation countermeasures has been recognised as a high priority in the US. At present, no approved drugs are available for the prevention or treatment of acute radiation syndrome, even though this is a top national priority. One promising investigational drug candidate for the indication of radioprotection is BIO 300. This agent is a medical radiation countermeasure that is intended for use as a prophylactic treatment for acute radiation syndrome. Novel products (such as BIO 300) that provide prophylactic protection are designed to be shelf stable for several years, more rapidly distributed and easily administered orally with a minimum of medical supervision.
Zenk
John L
JL
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D015507:Drugs, Investigational / Q000494:pharmacology; D006801:Humans; D011832:Radiation Injuries / Q000517:prevention & control*; D011839:Radiation, Ionizing; D011837:Radiation-Protective Agents / Q000494:pharmacology*
D000975:Antioxidants; D015507:Drugs, Investigational; D011837:Radiation-Protective Agents